Wonder Sciences

Wonder Sciences, founded in 2020 by serial entrepreneur Ryan Magnussen, is a mental health and wellness company operating at the intersection of psychedelic medicine, scientific research, and telehealth. The Los Angeles-based firm is structured around a four-pillar ecosystem designed to address mental health through a multi-faceted approach. Magnussen, whose background includes founding successful digital and media companies like Zentropy Partners, was inspired by his studies of Buddhist traditions and personal psychedelic experiences to create a platform for self-healing. His entrepreneurial journey, which began with a bungee jumping company at age 19, reflects a long-standing interest in pioneering new fields.

The company's primary product, Wondermed, is an at-home telehealth service that provides physician-partnered, low-dose ketamine-assisted protocols for anxiety and depression. This service is designed to be more accessible than traditional in-clinic treatments, enabling patients to undergo therapy from home. After a telehealth consultation to determine eligibility, patients receive a personalized kit that includes a low-dose ketamine lozenge. The protocol integrates this with patient-led holistic practices like meditation and breathwork to enhance the therapeutic effects of ketamine, which is known to promote neuroplasticity. The business model for Wondermed involves a monthly patient subscription of $199 for the program, which covers medication and support, while partner physicians bill patients separately for consultations.

Supporting this commercial offering is Wonder Research, the company's division for conducting clinical studies to develop evidence-based psychedelic protocols. Wonder Sciences also has plans for Wonder Clinics, physical mental health centers intended to offer a broader range of treatments including psychedelic-assisted therapies and neuroscience. The fourth pillar, Wonder Give, underscores a commitment to philanthropy by supporting non-profits that protect indigenous tribes and work to establish safety and efficacy guidelines for psychedelic medicine. In June 2022, Wonder Sciences announced it had raised $4.6 million in a seed funding round led by investors such as Phyto Partners, Tejo Ventures, and Ambria Capital, to facilitate the expansion of its Wondermed service.

Keywords: psychedelic medicine, mental healthcare, telehealth, ketamine therapy, clinical research, holistic wellness, mental health protocols, at-home treatment, neuroplasticity, somatic protocols